SEATTLE — Patients with proliferative vitreoretinopathy experienced improved visual acuity after receiving an intravitreal injection of infliximab after pars plana vitrectomy, according to a study.
At the American Society of Retina Specialists annual meeting, Ayman Elnahry, MD, PhD, said proliferative vitreoretinopathy (PVR) is the most common cause of failure of rhegmatogenous retinal detachment (RRD) repair.
“Multiple therapeutic agents have been tried as an adjunctive to RRD surgery with no consistent efficacy, and there are currently no medications approved for treating PVR,”